A brief summary of the issues involved around brand name drugs and their generic equivalents will be presented. These issues will include government regulatory specifications, production costs, and patent issues (term of patent, re-patenting of "new forms" alias "re-inventing the wheel"). Some examples of specific drugs will be mentioned in this context.